Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Cystoid macular edema (CME) secondary to retinal vein occlusion (RVO) significantly impairs vision.
• Intravitreal dexamethasone implants offer a potential therapeutic option for managing RVO-induced CME.

Purpose of the Study:

• To assess the efficacy, safety, and recurrence patterns of a first intravitreal dexamethasone implant in RVO-associated CME.
• To evaluate the timing of anatomical and functional recurrence after treatment.

Main Methods:

• A 6-month prospective case series of 26 eyes with RVO-induced CME.
• Evaluated best-corrected visual acuity (BCVA) and central subfield thickness (CST) changes.
• Defined and analyzed qualitative anatomical, quantitative anatomical, and functional recurrence patterns.

Main Results:

• 88% of eyes achieved a 3-line BCVA improvement by 2 months (P=0.02).
• Mean recurrence delay was approximately 4.1-4.4 months for different recurrence types.
• Qualitative anatomical recurrence preceded functional recurrence by an average of 14.4 days.

Conclusions:

• Intravitreal dexamethasone is effective for RVO-induced CME, including long-duration cases.
• The treatment demonstrates a favorable safety profile and delays recurrence.
• Further studies are recommended to investigate repeat treatments and combination therapies.